- +1
- +6
- Lower Saxony, Germany
Über
TMTTs are the future of Edwards – Estimated to be a more than $3 billion opportunity by 2024, Edwards will discuss its multiple transcatheter programs aimed at transforming care for the many patients suffering from mitral and tricuspid regurgitation. Edwards plans to launch one transformational therapy in Europe each year led by its CARDIOBAND and PASCAL programs.
Join the most innovative company in structural heart field.
Wünschenswerte Fähigkeiten
- Sales
- Medical Devices
- Sales
- Management
- Medical Devices
- Medical Devices
Berufserfahrung
- Other Sales
Sprachkenntnisse
- German